Tilray Inc (NASDAQ:TLRY) – Research analysts at Piper Jaffray Companies upped their Q1 2019 EPS estimates for shares of Tilray in a report released on Tuesday, March 12th. Piper Jaffray Companies analyst M. Lavery now expects that the company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.43). Piper Jaffray Companies currently has a “Overweight” rating and a $90.00 price target on the stock. Piper Jaffray Companies also issued estimates for Tilray’s Q2 2019 earnings at ($0.40) EPS, FY2019 earnings at ($1.39) EPS, Q1 2020 earnings at ($0.21) EPS and FY2020 earnings at ($0.21) EPS.
A number of other equities research analysts also recently commented on TLRY. Zacks Investment Research downgraded shares of Tilray from a “hold” rating to a “sell” rating in a report on Thursday, December 20th. Roth Capital upgraded shares of Tilray from a “neutral” rating to a “buy” rating in a report on Wednesday, February 20th. Jefferies Financial Group began coverage on shares of Tilray in a report on Friday, March 8th. They set an “underperform” rating and a $61.00 price target for the company. Finally, Seaport Global Securities began coverage on shares of Tilray in a report on Thursday, February 21st. They set a “neutral” rating and a $81.10 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Tilray currently has a consensus rating of “Hold” and a consensus price target of $106.52.
Institutional investors have recently added to or reduced their stakes in the stock. Exane Derivatives grew its holdings in Tilray by 1,833.0% in the fourth quarter. Exane Derivatives now owns 9,665 shares of the company’s stock valued at $683,000 after purchasing an additional 9,165 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Tilray in the third quarter valued at approximately $5,287,000. Zimmer Partners LP purchased a new stake in Tilray in the third quarter valued at approximately $3,591,000. CIBC World Markets Inc. purchased a new stake in Tilray in the third quarter valued at approximately $298,000. Finally, First Mercantile Trust Co. grew its holdings in Tilray by 35.4% in the fourth quarter. First Mercantile Trust Co. now owns 6,500 shares of the company’s stock valued at $459,000 after purchasing an additional 1,700 shares during the period. Hedge funds and other institutional investors own 7.88% of the company’s stock.
In other news, insider Brendan Kennedy sold 149,916 shares of Tilray stock in a transaction dated Thursday, January 24th. The shares were sold at an average price of $74.21, for a total transaction of $11,125,266.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CRO Edward Wood Pastorius, Jr. sold 29,422 shares of the business’s stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $72.57, for a total transaction of $2,135,154.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 199,916 shares of company stock valued at $14,787,514.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Read More: Dividend
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.